-------
Mr Rémi Charrier
StereoTools AG, www.stereotools.com
StereoTools is a Swiss MedTech company developing and providing guides for the future of brain surgery. Our product can be used to guide needles or electrodes at very specific regions of the brain in order to diagnose tumors and lesions or to treat movement disorders like Parkinson's disease via the use of Deep Brain Stimulators. In 2009 more than 100'000 of this type of procedures have been performed in Europe and 300'000 worldwide. This represents a market above 900 million CHF.
Mr Benoît Dagon
Imina Technologies AG, www.imina.ch
Nanomanipulation boosted by mobility! Imina Technologies helps researchers in nanotechnologies and life science to get faster and more reliable results, by providing them with intuitive and flexible micromanipulation solutions. The extreme simplicity of the miBot, an ultra compact mobile micro-robot with nanometer resolution motion, enables to significantly reduce the preparation time for setting-up an experiment and makes complex manipulations at nanoscale very easy to perform
Mr Francesco Dell'Endice
QualySense, www.qualysense.com
QualySense AG develops and markets high-speed sorting devices for online monitoring of food quality and safety parameters, and aims to become a global innovation leader in the field. Our proprietary technology enables companies in the agribusiness to control the entire production such that consumers’ standards are fulfilled.
Mr Nicolas Durand
Abionic, www.abionic.com
Based on an innovative nanotechnology approach, Abionic will develop and provide fast and low-cost screening tests for portable medical diagnostic use. As there are currently over 100 million people in Europe suffering from allergies, Abionic will firstly develop a novel personalized allergy diagnostic test that will allow patients to take the optimal medication.
Mr Jaime Garcia
Giraldez
Crisalix Sàrl, www.crisalix.com
Crisalix is the inventor of the first worldwide technology for 3D simulation based on physical properties of the patient and available through the Web, with application for plastic, aesthetic and reconstructive surgery. Crisalix is a spin-off from the Institute of Surgical Technology and Biomechanics (ISTB) from the University of Bern and Ecole Polytechnique Fédérale de Lausanne (EPFL), as a result of a research initiated in 2006 with the support of CO-ME network (Computer Aided and Image Guided Medical Interventions)
Ms Nina Geib
Virometix AG, www.virometix.com
Virometix develops a new generation of vaccines using its Synthetic Virus-Like Particle (SVLP) technology, which enables the creation of a novel type of synthetic nanoparticles. Similarly to real viruses, SVLPs can generate a strong and long-lasting immune response. However, unlike real viruses, SVLPs are made entirely by chemical synthesis with associated advantages in stability, safety, production and quality control, and are completely modular. This enables the design of tailored vaccines for the prevention and treatment of a broad range of infectious and chronic human diseases. Virometix is developing several vaccines including one against streptococcal diseases. (www.virometix.com)
Mr Alexander Ilic
Dacuda AG, www.dacuda.com
Dacuda develops and markets proprietary, patent pending technology for enabling fast and intuitive document scanning with handheld devices. Dacuda's technology bases on real-time feedback, video-stream stitching, and workflow integration. Dacuda's strength and competence is software which can stitch together hand-scanned content. This technology is used to build the world's first scanning computer mouse.
Mr Kilian Imfeld
3Brain, www.3brain.com
3Brain developed a new technology for in-vitro high-resolution electrophysiology. It is now available as a product (BioCAM4096) that consists of disposable bio-chips, of a compact high-speed data acquisition platform and of a control and analysis software. The system enables dense electrical activity monitoring of electrogenic cell cultures and provides researchers access to unique spatio-temporal details of network information. Current applications include both neuroscience and high-throughput drug discovery.
Ms Emanuela Keller
NeMoDevices AG, www.nemodevices.ch
NeMoDevices AG, founded in 2007 as a spin-off company from the University and ETH Zurich, stands for innovative neuromonitoring systems. The company is dedicated to optimizing diagnosis and treatment of patients with stroke and brain injuries in order to save lives and improve patient’s quality of life. NeMoDevices`s technologies are based on near infrared extinction and provide two single-use products: a minimal invasive probe (NeMo Probe) and a non-invasive patch (NeMo Patch), which allows monitoring brain blood flow and oxygenation in the Intensive Care Unit. By providing up-to-date and highly accurate key parameters at the bedside, the NeMo System enables a paradigm shift comparable to the one from visual flight to instrument flight. Thanks to the availability of NeMo System’s monitoring, decisions about treatments and therapeutic interventions can be made earlier, more accurate and with significantly higher confidence.
Mr Christopher Latkoczy
nanolytix AG, www.nanolytix.ch
Nanolytix covers the detection of nano-particles performing in-house and mobile service analysis of samples as well as the development of innovative technologies to produce and distribute validated turn-key analytical industrial standard instrumentations.
Mr Jan Lichtenberg
InSphero AG, www.insphero.com
InSphero’s biological microtissues help pharmaceutical companies to test new drugs in the laboratory more efficiently. Because of the patent-pending production technology, these microtissues resemble human native tissue in terms of structure and function much better than conventional tests. Therefore, they give pharmaceutical developers more insight into the efficacy of new drugs or into potential negative side effects. InSphero AG currently has six employees in its laboratories in Zurich and works with three global pharmaceutical companies in pilot studies
Mr Hicham Majd
labseed Sàrl, www.labseed.com
Medical devices of all materials, when implanted, induce the formation of a capsule around them that manifest as hard tissue contractions. No effective strategy is clinically available to prevent this capsular contraction. labseed offer an innovative solution to provide body implants of any kind with MYcoat smart surface coating that effectively suppresses capsular contraction. This strategy reduces the pain suffered by patients and increases the functionality, longevity and cost-effectiveness of medical devices
Mr Frederic Mauch
BioApply GmbH, www.bioapply.com
BioApply : Improved Bioresin for injected products such as BioSlippers. BioApply, a CTI certified start up based in Canton de Vaud, is currently among the market leaders in terms of sales of biodegradable retail bags. While this business line is forecasted to grow in the next few years, we now are dedicated to launch our new technology, an improved bioresin for injected products. Our goal is to commercialize our improved bioresin. Our first application is a biodegradable flip-flop (slipper, open shoe). The proprietary technology can be applied to a wide range of applications.
Mr Samuel Mueller
Mirasense AG, www.mirasense.com
Mirasense AG is the creator of ScanDK, the world's fastest and most accurate 1D barcode recognition technology for mobile phones. Our image-based barcode recognition provides a low-cost alternative to classical laser scanners throughout the entire supply chain and additionally enables a large number of novel consumer empowerment applications such as in-store price comparison or health-related applications.
Mr Matthias Peterhans
CAScination GmbH, www.cascination.ch
CAScination provides a navigation system for surgery on soft tissues. Similarly to the navigation system in a car, the surgical navigation system displays a map (of the patient) and guides the user to a desired target location (treatment area). This guidance information is displayed in a 3D augmented reality scene and allows for highly precise treatment of tumors. Navigated surgery has the potential to enable surgery on patients which cannot be treated with conventional surgical techniques. The CAS-One liver navigation system by CAScination has shown usability in a first clinical study and is now ready for sales as a medically certified device for the European market.
Mr Bastien Rachet
LFCM, www.epfl.ch
Fluorescence microscopy is a widely used technique in life sciences. However, high performances in detection come with a limitation on the area to be observed, slowing down large scale studies. Parallelization is a key to increase the throughput and the Large Field Confocal Microscope (LFCM) provides such a solution in the fluorescence imaging domain. The time needed to perform biochemical analysis or tissue studies is therefore substantially reduced. Furthermore, former impractical studies become possible.
Mr Johannes Reck
GetYourGuide AG, www.getyourguide.com
GetYourGuide is an ETH Zurich Spin-Off, which provides a platform for tours, attractions & activities. The website has been able to become the German market leader in this poorly penetrated touristic sector within less than one year. Currently GetYourGuide is deploying partnerships with major travel websites, such as travel.ch, hotel.de, MySwitzerland.com, Tripwolf among others.
Mr Marc Rocklinger
Power Insoles, www.power-insoles.com
Power Insoles develops and markets intelligent electronic shoe-insoles for diabetic people. These insoles are worn daily and measure foot plantar pressure continuously. They enable to prevent apparition of diabetic foot ulcers, which are responsible for more than half of lower limb amputation in the world ! These innovative and practical insoles will improve the quality of life of many, and reduce significant health care costs.
Mr Tej Tadi
Minmaze,
Mindmaze aims to be a one stop solution where hospitals and clinics can harness innovative 3D technology in combination with Neuro-imaging techniques to offer tailored solutions to their patients. The solution enables objective measurement of performance through brain activity patterns recorded while patients interact in different virtual environments. Therapists can treat more patients and engage and motivate patients by offering an immersive rehabilitation experience.
Mr Arik Zucker
Qvanteq GmbH, www.qvanteq.com
Qvanteq develops novel stent technologies to address and overcome the adverse effects of today's available coronary artery stents. A coronary stent is a small (metal) mesh tube which is being implanted into coronary arteries to prevent heart attacks.
You need to be logged in to add comments. Login
Congratulations to all Venture Leaders 2010! We are looking forward to hosting you here in Boston in June.
Youpa, I wish them an excellent trip. It's interesting to see that less ICT, but more micro-nano technologies appear. Venture leaders approach/package is just brilliant.
Congrats to the VL'10. And yes Raph, micro/nano rulez :) !